The tested CD19.CARs did exhibit some tonic signaling and in common clinical settings CD19.CARs are expected to receive ongoing stimulation of the CD19 specific receptor by ligation with B cells, which are constantly produced in the bone marrow of most patients even after remission of the treated hematological malignancy is achieved. The gene discussed is CD19; the disease is hematologic disorder.